Table 1 Patient demographics and surgical characteristics

Age (years old)

56.28 ± 10.19

57.87 ± 10.58

0.312

Height (cm)

157.95 ± 4.75

157.91 ± 6.21

0.956

Weight (kg)

59.84 ± 11.66

58.17 ± 8.97

0.290

BMI (kg/m²)

23.95 ± 4.30

23.33 ± 3.42

0.295

Comorbidities

Hypertension

19 (21.8%)

22 (25.3%)

0.721

Diabetes mellitus

10 (11.5%)

15 (17.2%)

0.388

Cardiac disease

2 (2.3%)

6 (6.9%)

0.278

Respiratory disease

1 (1.1%)

2 (2.3%)

1.000

Hepatic disease

5 (5.7%)

1 (1.1%)

0.211

Renal disease

1 (1.1%)

2 (2.3%)

1.000

ASA class, II/III (n [%])

84/3 (96.6%/3.4%)

79/8 (90.8%/9.2%)

0.211

Cancer staging

0.993

Carcinoma in situ

20 (23.0%)

20 (23.0%)

Stage I

31 (35.6%)

32 (36.8%)

Stage II

29 (33.3%)

29 (33.3%)

Stage III

7 (8.1%)

6 (6.9%)

Procedure type

0.171

BCS

52 (59.8%)

42 (48.3%)

MRM

35 (40.2%)

45 (51.7%)

Tumor site, left/right (n [%])

41/46 (47.1%/52.9%)

49/38 (56.3%/43.7%)

0.288

Surgical time (min)

63.86 ± 17.34

68.22 ± 18.80

0.114

Anesthetic time (min)

89.46 ± 20.01

94.52 ± 21.53

0.110

Emergence time (min)

8.38 ± 3.77

8.61 ± 3.66

0.684

Anesthetic consumption

Fentanyl (mcg)

110.92 ± 34.88

113.22 ± 29.49

0.639

Propofol (mg)

554.25 ± 182.84

549.17 ± 155.62

0.844

Rocuronium (mg)

50.46 ± 9.69

49.02 ± 8.49

0.300

Ce value of propofol (mcg/mL)

At conscious loss

3.48 ± 0.39

3.44 ± 0.40

0.577

At conscious recovery

0.78 ± 0.11

0.77 ± 0.12

0.893

Intraoperative NSAID use

38 (43.7%)

34 (39.1%)

0.644